Astrazeneca PLC (NYSE:AZN) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Monday, July 24th.
Other research analysts have also issued reports about the company. Jefferies Group LLC reissued a “hold” rating on shares of Astrazeneca PLC in a research report on Monday, April 10th. Credit Suisse Group raised Astrazeneca PLC from an “underperform” rating to a “neutral” rating in a research report on Friday, May 12th. UBS AG lowered Astrazeneca PLC from a “buy” rating to a “neutral” rating and decreased their target price for the company from $35.44 to $25.55 in a research report on Wednesday, April 5th. Leerink Swann reiterated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Astrazeneca PLC in a research note on Wednesday, May 17th. Finally, Barclays PLC reiterated an “overweight” rating on shares of Astrazeneca PLC in a research note on Thursday, July 13th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the company’s stock. Astrazeneca PLC has a consensus rating of “Hold” and an average target price of $33.39.
Astrazeneca PLC (NYSE:AZN) opened at 29.12 on Monday. The company has a market capitalization of $73.73 billion, a PE ratio of 19.10 and a beta of 0.74. The company’s 50-day moving average price is $31.67 and its 200 day moving average price is $31.48. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.60.
Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.46. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. Astrazeneca PLC’s revenue for the quarter was down 9.9% compared to the same quarter last year. During the same period last year, the company earned $0.83 EPS. On average, equities research analysts anticipate that Astrazeneca PLC will post $1.86 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Astrazeneca PLC (AZN) Lowered to Sell at BidaskClub” was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/astrazeneca-plc-azn-stock-rating-lowered-by-bidaskclub-updated-updated-updated.html.
Several hedge funds have recently bought and sold shares of the company. Hudock Capital Group LLC raised its stake in Astrazeneca PLC by 0.4% in the first quarter. Hudock Capital Group LLC now owns 6,773 shares of the company’s stock worth $210,000 after buying an additional 27 shares in the last quarter. First Financial Bank N.A. Trust Division raised its stake in Astrazeneca PLC by 0.7% in the first quarter. First Financial Bank N.A. Trust Division now owns 7,517 shares of the company’s stock worth $234,000 after buying an additional 50 shares in the last quarter. Beacon Investment Advisory Services Inc. raised its stake in Astrazeneca PLC by 0.7% in the first quarter. Beacon Investment Advisory Services Inc. now owns 7,571 shares of the company’s stock worth $236,000 after buying an additional 54 shares in the last quarter. Garrison Financial Corp raised its stake in Astrazeneca PLC by 0.5% in the second quarter. Garrison Financial Corp now owns 18,058 shares of the company’s stock worth $616,000 after buying an additional 86 shares in the last quarter. Finally, Parkside Financial Bank & Trust raised its stake in Astrazeneca PLC by 1.3% in the first quarter. Parkside Financial Bank & Trust now owns 7,040 shares of the company’s stock worth $219,000 after buying an additional 90 shares in the last quarter. Institutional investors own 14.30% of the company’s stock.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.